HSR22-124: Real-World Outcomes Among Patients With Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated With EGFR Tyrosine Kinase Inhibitors Versus Immunotherapy With or Without Chemotherapy in First-line Setting

Authors: Jon Apple, Rahul Shenolikar, Kevin De Silva, Ping Sun, Alexander Spira

Published: 2022-03-31

DOI: 10.6004/jnccn.2021.7187

Source: Full article

No abstract found.